Denosumab (prolia) for postmenopausal osteoporosis

MeSH terms

• Antibodies, Monoclonal / administration & dosage
• Antibodies, Monoclonal / adverse effects
• Antibodies, Monoclonal / economics
• Antibodies, Monoclonal / therapeutic use*
• Antibodies, Monoclonal, Humanized
• Bone Density Conservation Agents / administration & dosage
• Bone Density Conservation Agents / adverse effects
• Bone Density Conservation Agents / economics
• Bone Density Conservation Agents / therapeutic use*
• Denosumab
• Drug Administration Schedule
• Drug Costs
• Female
• Fractures, Bone / etiology
• Fractures, Bone / prevention & control*
• Humans
• Injections, Subcutaneous
• Osteoporosis, Postmenopausal / complications
• Osteoporosis, Postmenopausal / drug therapy*
• RANK Ligand / administration & dosage
• RANK Ligand / adverse effects
• RANK Ligand / economics
• RANK Ligand / therapeutic use*
• Treatment Outcome